ETR:BIO - Biotest Aktiengesellschaft Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: €0.00
  • Forecasted Upside: -100.00 %
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
€41.80
+0.30 (1.20%)

This chart shows the closing price for BIO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Biotest Aktiengesellschaft Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for BIO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for BIO

Analyst Price Target is €0.00
▼ -100.00% Downside Potential
This price target is based on 0 analysts offering 12 month price targets for Biotest Aktiengesellschaft in the last 3 months. The average price target is €0.00, with a high forecast of €0.00 and a low forecast of €0.00. The average price target represents a -100.00% upside from the last price of €41.80.

This chart shows the closing price for BIO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Biotest Aktiengesellschaft. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/3/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/3/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/1/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/30/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/28/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/26/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/27/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/27/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/15/2018equinetSet Price TargetNeutral€24.10
8/7/2018equinetSet Price TargetNeutral€24.10
5/14/2018equinetSet Price TargetNeutral€25.00
1/22/2018equinetSet Price TargetNeutral€18.00
8/11/2017equinetSet Price TargetNeutral€19.00
(Data available from 5/28/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/30/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
11/29/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
12/29/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
1/28/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/27/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/29/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/28/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/28/2022

Current Sentiment

  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Biotest Aktiengesellschaft logo
Biotest Aktiengesellschaft develops, manufactures, and sells biological medicines in Germany and internationally. It operates through Therapy, Plasma & Services, and Other segments. The company offers its products in hematology, clinical immunology, and intensive care medicine areas. Its products include Haemoctin and Vihuma for the treatment of haemophilia A acute therapy and prophylaxis; and Haemonine for haemophilia B acute therapy and prophylaxis. The company's products also comprise Cytotect CP biotest for cytomegalovirus infections; Fovepta for hepatitis B prophylaxis in neonates; Hepatect for prophylaxis of hepatitis B reinfection; Intratect and IgG Next Genration for primary immune and secondary antibody deficiency syndromes and autoimmune diseases, as well as neurological indications; Varitect for the treatment of varicella zoster virus infections; and Zutectra for hepatitis B re-infection prophylaxis after liver transplantation. In addition, it provides Albiomin and Biseko to restore and maintain circulating blood volume; Cofact for the treatment of clotting factors deficiency; Fibrinogen to treat congenital fibrinogen deficiency; Trimodulin for the community-acquired pneumonia and COVID-19; and Pentaglobin to treat bacterial infections. The company was formerly known as Biotest Serum-Institut GmbH and changed its name to Biotest Aktiengesellschaft in 1986. The company was founded in 1946 and is headquartered in Dreieich, Germany. As of January 21, 2022, Biotest Aktiengesellschaft operates as a subsidiary of Grifols, S.A.
Read More

Today's Range

Now: €41.80
Low: €41.80
High: €41.80

50 Day Range

MA: €42.24
Low: €41.10
High: €43.00

52 Week Range

Now: €41.80
Low: €28.30
High: €44.60

Volume

82 shs

Average Volume

1,927 shs

Market Capitalization

$827.04 million

P/E Ratio

N/A

Dividend Yield

0.19%

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Biotest Aktiengesellschaft?

The following Wall Street analysts have issued stock ratings on Biotest Aktiengesellschaft in the last year:
View the latest analyst ratings for BIO.

What is the current price target for Biotest Aktiengesellschaft?

0 Wall Street analysts have set twelve-month price targets for Biotest Aktiengesellschaft in the last year.
View the latest price targets for BIO.

What is the current consensus analyst rating for Biotest Aktiengesellschaft?

Biotest Aktiengesellschaft currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for BIO.

How do I contact Biotest Aktiengesellschaft's investor relations team?

Biotest Aktiengesellschaft's physical mailing address is Landsteinerstr. 5, DREIEICH, 63303, Germany. The company's listed phone number is +49-6103-8010. The official website for Biotest Aktiengesellschaft is www.biotest.com. Learn More about contacing Biotest Aktiengesellschaft investor relations.